Life Sciences Archive » September, 2019

Life Sciences - September, 2019

356 articles

• Sterigenics Says It Will Not Pursue Reopening Of Ill. Facility
• Abbott Worker's $9M Age-Bias Verdict Slashed To $1.1M
• Oregon Health Agency Floats Vaping Ban To Governor
• Fed. Circ. Judge Slams Amgen Patent's 'Utter Lack Of Clarity'
• FDA, DEA Collaborate On Warnings Over Opioid Sales
• DOJ Wins Bids To End FCA Suits Targeting Eli Lilly, Bayer
• Canada Urged To Regulate CBD As Natural Health Supplement
• AstraZeneca Hit With Another Seroquel XR Pay-For-Delay Suit
• Locke Lord Adds Jenner & Block IP Partner In Chicago
• Fed. Circ. Is Sanctioning Government Theft, Celgene Warns
• PTAB Cuts Down Two More Allergan Restasis Patents
• WTO Dispute Roundup: Members Gird For Appellate Freeze
• Glumetza Makers Slapped With 2 New Suits Over Price Hikes
• Ex-Shkreli Employee's Expanded $1.3M Fraud Suit Lives On
• Purdue's $38M Bonus Plan In Ch. 11 Draws Watchdog's Ire
• FTC Taking A Closer Look At $63B AbbVie-Allergan Deal
• Michigan E-Cig Ban Withstands Early Challenge
• CBD Cos. Lied About Dosages, Proposed Class Action Says
• Opioid Negotiation Class May Be Organic Procedure Evolution
• Cooley To Steer Vir Biotechnology's $150M IPO
• J&J Beats Investor's Suit Over Talc-Cancer Link
• Ex-Sanofi Employee Says Doctor Program Was For Kickbacks
• True Wellness Requires A Deeper Look At Atty Profession
• Three Firms Steer Sobi's $915M Dova Pharma Buy
• NY Rep. Collins Resigns, Plans Insider Trading Guilty Plea
• 35 Charged In $2.1B Telehealth Gene Test Fraud
• Walgreens, Vision Direct Ink $12M Contact Lens Antitrust Deal
• 2 Classes Certified In Suboxone Product-Hop Suit
• Antitrust Case Against IQVIA Will Join Larger Fight In NJ
• J&J Hit With $40M Verdict In Calif. Talc Cancer Trial
• Sanofi Beats First Bellwether In Chemo Drug Hair Loss MDL
• High Court Told Not To Review Lilly's $20M Cialis Patent Loss
• Abbott Gets Win In 20-Year-Old Age Bias Suit OK'd
• Washington To Ban Flavored Vape Products, Including THC
• Eye on ERISA: Q&A With McDermott's Ted Becker
• Keep Med Supply Pricing Suit Buried, Becton Urges 7th Circ.
• King & Spalding Directs $925M Gatan Sale To Ametek
• Invisalign Maker Slips Suit Over Clear Aligner Market, For Now
• 13 Firms To Steer 6-IPO Week Dominated By Biotechs
• Dispensary Chain Ends 2-State License Fight With Pot Shop
• Sequoia Ruling Dodges Debate Over Fund Docs As Contracts
• Vaping Illnesses Tied To THC Cartridges, CDC Says
• Robbins Geller To Lead Reckitt Stock-Drop Suit
• Pursuing Wellness
• Mylan Inks $30M SEC Deal After Not Disclosing EpiPen Probe
• Insurer Must Cover Wholesaler's $3.5M W.Va. 'Pill Mill' Deal
• Minn. AG Defends Insulin Suit Against Sanofi, Novo, Lilly
• J&J Launches Appeal Of $572M Okla. Opioid Judgment
• Avanir To Pay $108M Over Nuedexta Drug Kickback Scheme
• Vaping Industry Group Sues To Block NY's Flavored E-Cig Ban
• 'Negotiation Class' In Opioid MDL Is Unlawful, 6th Circ. Told
• Teva Can't Escape Investors' Price-Fixing Claims, Judge Says
• Two Essure Users Fight Uphill To Keep Injury Claims Alive
• Health Co. Hits Rival With TM Suit, Cites Emoji-Ridden Posts
• What To Do When A Private Equity Firm Wants Your Business
• FDA Issues Rare 2nd Warning Over Sleep Drug Promos
• Rival Can't Shake AngioDynamics' $145M Racketeering Suit
• How BigLaw Is Adapting To Plaintiff-Side Litigation
• Calif. Tells Judge J&J Must Pay $800M For Mesh Marketing
• Unpacking The Latest ITC Trends: Part 2
• Opioid MDL Judge Won't Withdraw Over Bias Charge
• Battle Lines Drawn For Opioid MDL's Bellwether Trial
• Judge Blocks Talk Of J&J Mesh Sales Revenue In Calif. Trial
• Gov't Claimants Want Insys Bankruptcy Converted To Ch. 7
• J&J, Colgate Can't Ditch $10M Award In Calif. Talc Trial
• DOJ Targets Telehealth Fraud Tied To Genetic Testing
• NantHealth Urges Chancery To Boot Research Deal Suit
• FDA Acting Head Says E-Cig Policy To Be Final Soon
• Dems Defend Drug Price Negotiation Bill Against GOP Outcry
• J&J Beats Tax Ruling Over Insurance Coverage Outside NJ
• Del. Justices Warned Not To Upend Fabric Of Disclosure Law
• Pursuing Wellness: A Focus On Firm Holistic Health Training
• THC Vaping Health Issues Warrant Safety Standards
• 3 Unanswered Tax Questions Facing M&A Attorneys
• Cannabis Delivery Framework Gets Mass. Commission's OK
• Hogan Lovells Adds Corporate Pro To Life Sciences Group
• Judging A Book
• Opioid MDL Judge Rejects J&J's Attack On Trial Format
• Abilify MDL Judge Boots 149 Claimants From Settlement
• Rochester Drug To Lead ADHD Generic Delay Class
• House Dems, Republicans Split On Cause Of Vaping Deaths
• Delaware Judge Misread Key Data, Stimwave Tells Fed. Circ.
• Ex-PetMed Exec Cuts Deal With SEC In Insider Trading Suit
• Doctor Can't Shake Convictions In $100M Referral Scheme
• DOJ Charges More Doctors In Appalachia Opioid Sweep
• Cardinal Health Board Wants Opioid Derivative Suit Axed
• Mass. Vape Ban Draws Ire Of State Pot Commissioner
• J&J Unit Escapes Suit Over Breast Implant Warnings
• Judge Jackson Reviews 'When Should Law Forgive?'
• Levi & Korsinsky, Bernstein Vie For Lead In Karyopharm Suits
• Fed. Circ. Rejects Injunction Bid In Orthodontic IP Row
• 11th Circ. Affirms Foreclosure Of Inyx Fraudster's Fla. Home
• China Biologic Committee To Weigh $4.59B Take-Private Bid
• Ex-FDA Director Says Agency Found J&J's Mesh Labels OK
• HHS Can Force Drug Prices In TV Ads, DC Circ. Hears
• Cannabis Atty Wants To Take Legalization Fight To Congress
• Disclosures Let Keryx Escape Kidney Drug Stock Suit
• Allergan Hit With Suit Over Recalled Breast Implants
• DOJ Goes After Philly Pharmacy For $1M In Bogus Billing
• Loestrin Judge Assigns Antitrust Homework Before Hearing
• Pursuing Wellness: Steps Toward A Supportive Firm Culture
• Wisconsin Lawmakers Introduce Medical Marijuana Bill
• 4 Biotech Firms Freshen Pipeline With IPOs Totaling $526M
• PTAB Should've Axed Cancer Detection Patent, Fed. Circ. Told
• Stats Show Cannabis Patents Are Underutilized
• J&J Beats Bias Suit From Woman Who Sought Exec Position
• CFIUS Risk Review Rules May Draw Attention To US Biotech
• J&J Escapes Fla. Pelvic Mesh Suit Also Aimed At Subsidiary
• Marketing By Vape Cos. 'Severely' Limited In LA Settlement
• Pradaxa User's Win Could Doom Thousands Of Other Suits
• Leading House Dem Wants Drug 'Hopping' Banned
• Allergan Investor Tries To Block $63B AbbVie Deal Over Info
• J&J's Litigation Bravado In Sharp Relief After Epic Opioid Trial
• Buyers Win Class Cert. In Blood Clot Drug Monopoly Suit
• J&J Gets Woman's $20M Mesh Award Trimmed To $15M
• Seven Firms To Steer 4 IPOs Raising $1.8B, Led By Peloton
• Pursuing Wellness: Mental Health Education As A Firm Priority
• Drugmaker Amag Under Pressure From Activist Investors
• GAO Report Illuminates Insurer Influence On Drug Discounts
• FDA Releases Proposed Rule On E-Cig Applications
• FDCA Doesn't Apply To Convicted NECC Workers, Judge Told
• Drug Suppliers Admit To UK Market Fixing, Watchdog Says
• Split DC Circ. Revives Howard U. Veterinarian's Firing Suit
• Jury's Task In Ohio Opioid MDL Trial Divides Drug Cos.
• Roundup, Essure Suits On A Collision Course, Judge Worries
• Cynosure Says Mass. Law Allows No 'Re-Do' Of False Ad Suit
• DOJ Allowed Into 7th Circ. Arguments On Syringe Price-Fixing
• Dem, GOP Lawmakers Ask FDA To Clear Path For CBD Retail
• J&J, Expert Debate If Asbestos In Talc Is 'Urban Legend'
• Pharmacy, PE Fund Ink $21M Deal To End FCA Kickback Suit
• Suboxone Maker's 'Gross Manipulation' Prompts $3M Fee Bid
• TridentUSA's $9.5M Medicare Scheme Settlement Gets OK
• Walgreens Settles Out Of 1-800 Contacts Antitrust Suit
• Purdue Files Ch. 11 Suit Seeking Stay Of Opioid Litigation
• Medical Device Co. Escapes Sabotage Suit Against Subsidiary
• Ex-Pharmacy Head Gets 33 Months In Misdosed Drugs Case
• Pursuing Wellness: A Firm's Work With Mental Health Experts
• House Democrats Unveil Drug Pricing Bill Opposed By GOP
• Rite Aid Gets Claims Trimmed In Deceptive Labeling Suit
• Searching For A Legal Pathway For CBD Products
• Purdue Loses Bid To Toss Mass. Suit Amid Ch. 11 Stay Fight
• ERISA Suit Over DST's 401(k) Plan Management Is Trimmed
• AbbVie Dodges Suit Over $100M Stock Drop
• FDA Launches Criminal Probe Into Vaping Deaths, Illnesses
• Ginkgo Lands $290M Cell Programming-Focused Series E
• Insys Ch. 11 Sale Of Controversial Drug OK'd With New Limits
• Woman's J&J Talc Bottle Contained Asbestos, Expert Says
• J&J Talc Supplier Given Time To Negotiate Insurance Deal
• Pa. Judge Questions 'Economics' Of Endo Antitrust Claims
• Skin Treatment Developer Can Use Lender Cash In Ch. 11
• Novartis Halts Zantac Distribution, Citing Impurities
• Fed. Circ. Refuses To Add Time To Intra-Cellular Patent Term
• TridentUSA Ch. 11 Plan Wins Court Approval
• Ark. Wants 'Biased' Judge Tossed From All State Cases
• W. Va. Hits J&J, Ethicon With Pelvic Mesh Suit
• Retina Drug Co. Can't End Claims It Misled Investors
• Pursuing Wellness: When A Firm Brings Counseling On Site
• Skadden-Led Envista Tops 2 Health Care IPOs Totaling $764M
• Outsourcing Facilities Face Rising Drug Compounding Risks
• Attys Seek $5M Award In AbbVie $16.7M Inversion Settlement
• Opioid 'Negotiation Class' Justifies DQ Bid, Distributors Say
• Inyx Fraudster's Wife Appeals Foreclosure By Deutsche Bank
• Bausch & Lomb Inks $10M Deal In Contact Lens Price-Fix Suit
• White House Dem Hopefuls Raise Pharma Deal Worries
• ITC Halts Dumping Probe Of Mexican Thermoplastic Sheets
• Attys Say SEC Can't Tie Firm To Sham PixarBio Merger
• Mintz Adds Ex-Cooley Life Sciences Trademark Pro In NY
• Foreign Patentees, Heed Fed. Circ. Jurisdiction Ruling
• Pharma Giants Can't Shake Ariz. Hospital's Opioid RICO Suit
• Purdue Says 'Lives, Dollars' At Stake In Bankruptcy Case
• Couple Stole Key Research From Hospital, Feds Say
• McConnell Wants CBD Enforcement Guidelines, Now
• Fed. Circ. Must Rethink Upholding Cancer Drug IP, Zydus Says
• Pa. Jury Urged To Punish J&J For Pushing Risperdal On Kids
• Pursuing Wellness: Inside A Firm Meditation Program
• Merck Trade Secret Suit A Ploy To Aid Patent Case, Pfizer Says
• 2 Fed. Circ. Decisions May Signal Pro-Patentee Swing
• 5th Circ. Says Noncompete Fight Doesn't Belong In Texas
• Clinical Stage Biopharma Co. Sienna Hits Ch. 11 In Del.
• Weil Was Upfront About Repping Insys In Ch. 11, Atty Says
• 4 Key Takeaways As Opioid MDL Distributors Seek Judge's DQ
• Fla. House Can Wade Into Medical Pot Law Case, Panel Says
• Kite Pharma Hit With Patent Suit Over Cancer Drug
• PTAB Says Mass. Biotech's Milk Patent Ineligible For Review
• Scientist Tells Calif. Court J&J Mesh Doesn't Degrade
• Top 5 Modern Tax Challenges For Digital Health Companies
• Generic Cos. Pan 'Irrelevant' Doc Demands In Price-Fix Case
• Investors Say Cancer Drug Co. Hyped Up Trial Results
• PTAB Rejects Stryker's Challenge To Medical Suture Patent
• Sanofi Faces 1st US Suit Over Likely Carcinogen In Zantac
• Pfizer's Tax Interest Row Belongs In Claims Court: 2nd Circ.
• Early Sampling Of Electronic Info Is Underutilized In Discovery
• Split Fed. Circ. Upholds Term Adjustment For Antibody Patent
• Dissent Exposes Flaws In Fed. Circ. ANDA Patent Holding
• Momenta, Sandoz Push For Sanctions In Blood Clot Drug Suit
• J&J Talc Supplier's $7.2M Deal With Insurers Faces Pushback
• Sentry Data, CVS Reach Deal In Antitrust Fight
• Opioid MDL Cos. Accused Of 'Inventing' Comments By Judge
• 3 Firms Guide Near-$2B Deal For Alder BioPharmaceuticals
• Court Is Wrong Place For Monopoly Case, E-Scrip Co. Says
• Teva Wants Pa. Investor Suit To Join Others In Conn.
• Jury Left In Dark On Key Trial Issue, Antrim Tells 7th Circ.
• Purdue Pharma Seeks To Halt Opioid Suits With Ch. 11 Filing
• Opioid MDL Judge Deserves DQ For Bias, Distributors Say
• Jones Day Attys 'Very Much Regret' Grand Jury Redaction Slip
• Cos. Reach $9.5M Deal For Selling Non-FDA Cleared Devices
• High Prices Are Side Effect Of AbbVie-Allergan Deal, Feds Told
• Taxation With Representation: Wachtell, McDermott, Latham
• DOJ Asks To Argue In Health Cos.' Syringe Price-Fix Appeal
• 3rd Circ. Sends J&J Remicade Antitrust Fight to Arbitration
• 6 Firms To Steer Health Care, Tech IPOs Set To Raise $1.5B
• AbbVie Investors Ask To Drop Ill. Humira Kickback Suit
• Rakoff Scolds Gov't, Sets Life Spine Kickback Trial For 2020
• DEA Blocking Medical Cannabis Research Licenses, Lab Says
• Frayed Family IP Royalty Biz Gets Chancery Appraisal Look
• Purdue's Sacklers Shifted $1B Amid Opioid Fight, NY AG Says
• Drug Pricing Site Can't Escape Pharmacy Groups' Blacklists
• J&J Trims Claims From Colo. Man's Hernia Mesh Suit
• Rising Star: Quinn Emanuel's Matthew Robson
• Endo Says Drop Direct Buyers' Cert. Bid In Pay For Delay Row
• Goodwin, Latham Steer Life Sciences IPOs Totaling $244.5M
• Meet The Attys Leading The Opioid MDL 'Negotiation Class'
• U. Of Minn. Urges Supreme Court To Consider PTAB Immunity
• Quest Cleared In Cedars-Sinai Trade Secrets Row
• The Factors Courts Consider In Deposition Location Disputes
• $10M Award In J&J, Colgate Talc Trial Must Go, Judge Told
• Vectura Gets $10M Added To $90M Inhaler IP Award
• Purdue Bankruptcy May Leave State AGs Out In The Cold
• Pradaxa User's $542K Jury Win Upheld, Despite 'Close Call'
• 3rd Circ. Says No Hearing Guarantee For FCA Suit Dismissal
• PTAB Says Not Unfair To Review Amgen Chemo Patents
• CBD Cos. Fall Short On Testing And Labeling, Watchdog Says
• Patent Bill Would 'Do More Harm Than Good,' Lawmakers Told
• NY Rep. Collins Denies Feds' Redrawn Insider Trading Case
• 3rd Circ. Revives State-Law Fraud Claims By Merck Opt-Outs
• Vanda Pharma Investor Accuses Brass Of Off-Label Marketing
• Biopharma Co. Investors Allege Voting Rule Fouls In Del. Suit
• Rising Star: Greenberg Traurig's Fang Xie
• What To Consider Before Filing For A Rule 57 Speedy Hearing
• Creative Ways To Challenge Master Complaints In MDLs
• Simpson Thacher Steers Genomics' $390M Upsized IPO
• Skadden-Led SmileDirectClub Prices $1.3B IPO Above Range
• PTAB Weighs Whether Cattle Breeding Patent Is Obvious
• Jones Day Needs Mea Culpa To Avoid Grand Jury Flub Fallout
• 6th Circ. Won't Reinstate DQ'd BakerHostetler In Opioid MDL
• J&J Can't Duck Fla. Pelvic Mesh Suit Over Expert Evidence
• Reed Smith's LA Office Adds 2 Arent Fox Employment Alums
• Stymied By Imerys Ch. 11, Talc Case Returns To Lower Court
• Bull Semen Sorting Co. Wins $8.5M From Rival In IP Trial
• China Spares 16 US Goods From Duties Ahead Of Talks
• Opioid MDL 'Negotiation Class' Wins Approval
• Swiss Biotech Acquires Maker Of Celiac Drug Nearing Trials
• Rising Star: Fenwick & West's Robert Counihan
• Purdue To Settle Thousands Of Opioid Suits, File Bankruptcy
• Biogen Tells 1st Circ. Firing Was Unrelated To Mental Health
• Jones Day Faces Sanctions Threat After Redaction Flub
• Investors Say Suit Over Philip Morris E-Cig Sales Must Go On
• Reviewing Recent FDA Activity In Bulk Drugs Lists
• White House Prepares To Ban Flavored E-Cigs
• J&J Hit With $37.3M Verdict In NJ Talc Case
• Jones Day Botches Grand Jury Redaction In Attack On DOJ
• FDA Faces Free Speech Issues With Juul Warnings
• Canadian Cannabis Biz Hit With Investor Suit Over $143M IPO
• J&J Says Science Backs Its Talc At Opening Of Calif. Retrial
• Organon Whistleblowers Acted As Law Expects, 1st Circ. Says
• Fed. Circ. OKs Ax Of Surgical IP At Heart Of $10M Settlement
• Rising Star: Butler Snow's Alyson Jones
• Stem Cell Biz Facing Fraud Claims Declares Bankruptcy
• Weil Downplayed Atty Conflict, Convicted Insys Exec Says
• Ex-NHL Owner Accuses SEC Of Icing Document Request
• Simpson Thacher-Led Genomics Co. Ups IPO Target To $342M
• Baxter International To Pay Up To $230M For Cheetah Medical
• Dr. Reddy's, Hospira Want Full Fed. Circ. To Redo Lilly IP Win
• Why I Became A Lawyer: Expanding The Meaning Of Diversity
• Purdue, Opioid Distributors Can't Dodge RICO Claims In MDL
• Del. Judge 'Unlikely' To Halt True Health Medicare Payments
• J&J Wants Mistrial For Struck Talc Trial Closing Arguments
• Mallinckrodt To Sell BioVectra To HIG For Up To $250M
• J&J Hid Asbestos In Talc, Woman Tells 2nd Jury After Mistrial
• Feds Ask To Delay Proposed Subsys Sale
• Fed. Circ. Won't Rehear OxyContin Patent Claims
• 13 States Urge 6th Circ. To Block Ohio Opioid Bellwether
• Rising Star: Arnold & Porter's Eric Rothman
• 9th Circ. Revives Decade-Old Medicare Fraud Qui Tam Suit
• $10M Award May 'Raise Stakes' For Firing Mass. Profs
• Genentech Gets Taiwanese Co. To Abandon Biosimilars
• Datadog Leads IPO Flurry Expected To Raise $729M Combined
• State Law Issues The Court Missed In Cancer Drug Trial Case
• Juul Illegally Marketed E-Cigs As Safe To Youths, FDA Says
• Law360 Names Top Attorneys Under 40
• Fed. Circ. Clouds Landscape For Medical Treatment Patents
• Stryker Must Pay For IP Marking Failure, Acantha Says
• Biopharma Co. Regulus Dodges Stock Suit Over Drug Trials
• Exec Accused As Part Of $1.2B Fraud Scam Enters Guilty Plea
• Edibles Co. Sees TM Claims Tossed Over Pot's Illegal Status
• Deals Rumor Mill: LGC, G4S, Symantec
• Lone Star Laterals: Skadden, Haynes and Boone, Locke Lord
• 9 Firms To Guide 6 IPOs Eyeing Nearly $2.2B To Start Sept.
• Zicam Maker Hit With Patent Suit Over Nasal Spray Formula
• Womble Bond Boosts Product Liability Group In Atlanta
• Mallinckrodt Pays $24M To Exit Opioid MDL Bellwethers
• Japan's Sumitomo Dainippon Mulls $3B Roivant Drug Buy
• Why Opioid Suits Avoid GCs — And Why That Could Change
• Discovery Counsel Vital In All Phases Of Mass Tort Litigation
• Fed. Circ. Probes If Galderma Bound By Statements To PTAB
• Alcor Wins Bid To Overturn $6.5M Blood Testing IP Verdict
• 4 Key Takeaways As Ohio AG Fires Torpedo At Opioid MDL
• CVS-Aetna Review Ends In Parting Shots & Punctuation!
• Fed. Circ. Backs Genentech's Win On Phigenix Cancer Patent
• State Immunity Isn't Free-Rein On Venue, Fed. Circ. Says
• Pa. Judge Questions Standing For Health Fund In Opioid Case
• Mylan Tells Fed. Circ. That Sanofi Insulin Patents Not Special
• Mallinckrodt Pays $15M In 'Wine And Dine' FCA Case
• Ex-Aegerion CEO Says Ch. 11 Plan Vote Is Unfair
• European Investors Lead Medical Co.'s $44M Funding Round
• How The Wayback Machine Can Strengthen Your Case
• Colgate Tries To Narrow ERISA Suit Over Lump-Sum Payouts
• Bellus Health Raises $70M In Upsized Stateside IPO
• Pay-For-Delay Bill Goes Too Far, Conservative Org. Says
• J&J Wouldn't Risk 'Golden Egg' With Talc Warning, Jury Told
• Cedars-Sinai Doc Toiled 15 Years To Invent IBS Test, Jury Told
• 1st Circ. Weighs Payout For Fired Abiomed Exec
• Whether Opioid Crisis Is 'Public Nuisance' Up To Jury: Judge
• Pharmaceutical Cos., Shipping Co. Settle Kickbacks Suit
• J&J Asks Court To Toss 401(k) Savers' Suit Over Stock-Drop
• J&J Must Face Upcoming Risperdal Punitive Damages Trial
• Gilead Says HIV 'No Generic' Suit Is Baseless
• Stryker To Buy Pair Of Medical Tech Cos. For Up To $500M
• Fed. Circ. Judge 'Bewildered' Teva Got $235M Verdict Nixed
• Former FDA Head Can Testify In Sanofi Hair Loss Trial
• Weil Atty's Closing Argument Struck As J&J Talc Trial Wraps
• Pharma Co. Gets False Ad Suit Over Anesthetic Drug Trimmed
• CVS-Aetna Merger Cleared After Unprecedented Court Battle
• Skadden Steers Danaher Dental Unit's Potential $600M IPO
• Mississippi's Mental Health System Violates ADA, Judge Says
• Risks To Avoid When Conducting Virtual Clinical Trials
• Mail-Order Fecal Analysis Startup Files For Bankruptcy
• Fed. Circ. Muddies Waters On Method-Of-Treatment Patents
• Deals Rumor Mill: Poshmark, Lindsay Goldberg, Selecta
• Draft Civil Procedure Jurisdictional Rule Needs A Tweak
• Vensana Capital Wraps Up Inaugural Fund With $225M In Tow
• Opioid MDL Jury Will Weigh 'Complete Failures' By Drug Cos.
• Practicality Key In Suboxone Class Cert. Bid, Judge Suggests
• Lack Of Asbestos 'Biomarkers' Looms Over J&J Talc Trial
• CVS Mad About Findings, Not Discovery Pace, Sentry Says
• Quest Diagnostics Can't Use High Court To Evade TCPA Case
• Stryker Gets Ax Of Ex-NFL Player's Pain Pump Claims
• Monsanto Says LA County's PCB Suit Filed Too Late
• Fed. Circ. Pulls Contested Line In Its Sandoz Biosimilar Ruling
• Pharma Deal Made Monopoly For Diabetes Drug, Buyer Says
• Vertex Sets Sights On Diabetes Cure With $950M Semma Buy
• 5 Health Care IPOs Could Total $682M, Led By Genomics Biz
• Pharma Group Fights Injunction For Blacklisted Pricing Site
• Compliance Monitor May Help With CFIUS Approval
• Skadden-Led Orthodontics Biz Launches Potential $1.2B IPO
• Bankrupt Insys Plans Fentanyl Spray Sale To Competitor